Drug Profile

RTX IL 12

Alternative Names: mRBC-IL-12; RTX-IL-12

Latest Information Update: 28 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rubius Therapeutics
Developer Rubius Therapeutics [CEASED]
Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Cell replacements; Natural killer cell stimulants; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Mar 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
31 Dec 2022 Discontinued - Preclinical for Cancer in USA (Parenteral) (Rubius Therapeutics website, December 2022)
29 Mar 2019 Pharmacodynamics data from a preclinical trial in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com